Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 10:02 PM
Ignite Modification Date: 2025-12-24 @ 10:02 PM
NCT ID: NCT03439332
Eligibility Criteria: Inclusion Criteria: * Patients diagnosed with Glioblastoma grade IV WHO with histopathological confirmation * Age \>18 years at diagnosis * Patients with access to the preoperative and postradiotherapy MRI studies using 1.5 Tesla (T) or 3T scanners, including: pre and post gadolinium T1-weighted MRI, T2-weighted MRI, FLAIR MRI, Dynamic Susceptibility Contrast (DSC) T2\*-weighted perfusion, Dynamic Contrast Enhancement (DCE) T1-weighted perfusion (optional) and Diffusion Weighted Imaging (DWI) (optional) * WHO performance score between 0 and 2 * Patients with Karnofsky Performance Score (KPS) of ≥ 70% Exclusion Criteria: * Patients with congestive heart failure within 6 months prior to study entry (New York Heart Association ≥ Grade 3) * Uncontrolled or significant cardiovascular disease, including: myocardial infarction and transient ischemic attack or stroke within 6 months prior to enrollment, uncontrolled angina within 6 months, diagnosed or suspected congenital long QT syndrome, any history of clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation or Torsades de pointes) and clinically significant abnormality on electrocardiogram (ECG) * Pulmonary disease including or greater than grade 2 dyspnea or laryngeal edema, grade 3 pulmonary edema or pulmonary hypertension according to CTCAE 4.03
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT03439332
Study Brief:
Protocol Section: NCT03439332